Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania Show more

125 Strafford Avenue, Wayne, PA, 19087, United States

Biotechnology
Healthcare

Market Cap

1.737B

52 Wk Range

$18.23 - $151.18

Previous Close

$122.06

Open

$124.08

Volume

315,340

Day Range

$123.93 - $134.40

Enterprise Value

1.673B

Cash

63.57M

Avg Qtr Burn

-7.878M

Insider Ownership

19.92%

Institutional Own.

80.66%

Qtr Updated

09/30/25